Clonazepam Explained

Watchedfields:changed
Verifiedrevid:458436513
Imagel:Clonazepam 200.svg
Widthl:150
Imager:Clonazepam ball-and-stick model.png
Widthr:150
Pronounce:kləˈnazɪpam, kloe-NAZ-e-pam
Tradename:Klonopin, Rivotril, Paxam, others[1]
Dailymedid:Clonazepam
Pregnancy Au:B3
Pregnancy Au Comment:[2]
Dependency Liability:Physical

Very HighPsychological

Moderate

Addiction Liability:Moderate[3] [4]
Routes Of Administration:oral, intramuscular, intravenous, sublingual
Class:Benzodiazepine
Atc Prefix:N03
Atc Suffix:AE01
Legal Au:S4
Legal Br:B1
Legal Ca:Schedule IV
Legal De:Rx-only/Anlage III
Legal Nz:Class C
Legal Uk:Class C
Legal Us:Schedule IV
Legal Un:Psychotropic Schedule IV
Legal Status:Rx-only
Bioavailability:90%
Protein Bound:≈85%
Metabolism:Liver (CYP3A)
Metabolites:7-aminoclonazepam
7-acetaminoclonazepam
3-hydroxy clonazepam[5] [6]
Onset:Within an hour
Elimination Half-Life:19–60 hours
Duration Of Action:8–12 hours
Excretion:Kidney
Cas Number:1622-61-3
Pubchem:2802
Iuphar Ligand:6963
Drugbank:DB01068
Chemspiderid:2700
Unii:5PE9FDE8GB
Kegg:D00280
Chebi:3756
Chembl:452
Iupac Name:5-(2-Chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one
C:15
H:10
Cl:1
N:3
O:3
Smiles:O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1
Stdinchi:1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)
Stdinchikey:DGBIGWXXNGSACT-UHFFFAOYSA-N

Clonazepam, sold under the brand names Klonopin and Rivotril, is a medication used to prevent and treat anxiety disorders, seizures, bipolar mania, agitation associated with psychosis, obsessive–compulsive disorder, and akathisia.[7] It is a long-acting[8] tranquilizer of the benzodiazepine class. It possesses anxiolytic, anticonvulsant, sedative, hypnotic, and skeletal muscle relaxant properties. It is typically taken orally (swallowed by mouth) but is also used intravenously.[9] Effects begin within one hour and last between eight and twelve hours in adults.[10] [11]

Common side effects may include sleepiness, poor coordination, and agitation.[7] Long-term use may result in tolerance, dependence, and life-threatening withdrawal symptoms if stopped abruptly.[7] [12] Dependence occurs in one-third of people who take benzodiazepines for longer than four weeks. The risk of suicide increases, particularly in people who are already depressed.[7] Use during pregnancy may result in harm to the fetus.[7] Clonazepam binds to GABAA receptors, thus increasing the effect of the chief inhibitory neurotransmitter γ-aminobutyric acid (GABA).[13]

Clonazepam was patented in 1960 and went on sale in 1975 in the United States from Roche.[14] [15] It is available as a generic medication.[7] In 2021, it was the 46th-most commonly prescribed medication in the United States, with more than 14million prescriptions.[16] [17] In many areas of the world, it is commonly used as a recreational drug.[18] [19]

Medical uses

Clonazepam is prescribed for short-term management of epilepsy, anxiety, obsessive–compulsive disorder, and panic disorder with or without agoraphobia.[20] [21] [22]

Seizures

Clonazepam, like other benzodiazepines, while being a first-line treatment for acute seizures, is not suitable for the long-term treatment of seizures due to the development of tolerance to the anticonvulsant effects.

Clonazepam has been found effective in treating epilepsy in children, and the inhibition of seizure activity seemed to be achieved at low plasma levels of clonazepam.[23] As a result, clonazepam is sometimes used for certain rare childhood epilepsies, but it has been found to be ineffective in the control of infantile spasms.[24] Clonazepam is mainly prescribed for the acute management of epilepsies. Clonazepam has been found to be effective in the acute control of nonconvulsive status epilepticus; the benefits, though, tended to be transient in many people, and the addition of phenytoin for lasting control was required in these patients.[25]

It is also approved for treatment of typical and atypical absences (seizures), infantile myoclonic and akinetic seizures.[26] A subgroup of people with treatment resistant epilepsy may benefit from long-term use of clonazepam; the benzodiazepine clorazepate may be an alternative due to its slow onset of tolerance.[13] [27]

Anxiety disorders

The effectiveness of clonazepam in the short-term treatment of panic disorder has been demonstrated in controlled clinical trials. Some long-term trials have suggested a benefit of clonazepam for up to three years without the development of tolerance.[31] Clonazepam is also effective in the management of acute mania.[32]

Muscle disorders

Restless legs syndrome can be treated using clonazepam as a third-line treatment option, as the use of clonazepam is still investigational.[33] [34] Bruxism also responds to clonazepam in the short term.[35] REM sleep behavior disorder responds well to low doses of clonazepam.[36] It is also used for:

Other

Contraindications

Adverse effects

In September 2020, the U.S. Food and Drug Administration required the boxed warning be updated for all benzodiazepine medicines to describe the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions consistently across all the medicines in the class.[46]

Common

Less common

Occasional

Rare

The long-term effects of clonazepam can include depression,[13] disinhibition, and sexual dysfunction.[72]

Drowsiness

Clonazepam, like other benzodiazepines, may impair a person's ability to drive or operate machinery. The central nervous system depressing effects of the drug can be intensified by alcohol consumption, so alcohol should be avoided while taking this medication. Benzodiazepines have been shown to cause dependence. Patients dependent on clonazepam should be slowly titrated off under the supervision of a qualified healthcare professional to reduce the intensity of withdrawal or rebound symptoms.

Withdrawal-related

Benzodiazepines such as clonazepam can be very effective in controlling status epilepticus, but, when used for longer periods of time, some potentially serious side-effects may develop, such as interference with cognitive functions and behavior.[74] Many individuals treated on a long-term basis develop a dependence. Physiological dependence was demonstrated by flumazenil-precipitated withdrawal.[75] Use of alcohol or other CNS depressants while taking clonazepam greatly intensifies the effects, including side effects, of the drug.

A recurrence of symptoms of the underlying disease should be separated from withdrawal symptoms.[76]

Tolerance and withdrawal

See main article: Benzodiazepine withdrawal syndrome. Like all benzodiazepines, clonazepam is a GABA-positive allosteric modulator.[77] [78] One-third of individuals treated with benzodiazepines for longer than four weeks develop a dependence on the drug and experience a withdrawal syndrome upon dose reduction. High dosage and long-term use increase the risk and severity of dependence and withdrawal symptoms. Withdrawal seizures and psychosis can occur in severe cases of withdrawal, and anxiety and insomnia can occur in less severe cases of withdrawal. A gradual reduction in dosage reduces the severity of the benzodiazepine withdrawal syndrome. Due to the risks of tolerance and withdrawal seizures, clonazepam is generally not recommended for the long-term management of epilepsies. Increasing the dose can overcome the effects of tolerance, but tolerance to the higher dose may occur and adverse effects may intensify. The mechanism of tolerance includes receptor desensitization, down regulation, receptor decoupling, and alterations in subunit composition and in gene transcription coding.[13]

Tolerance to the anticonvulsant effects of clonazepam occurs in both animals and humans. In humans, tolerance to the anticonvulsant effects of clonazepam occurs frequently.[79] [80] Chronic use of benzodiazepines can lead to the development of tolerance with a decrease of benzodiazepine binding sites. The degree of tolerance is more pronounced with clonazepam than with chlordiazepoxide.[81] In general, short-term therapy is more effective than long-term therapy with clonazepam for the treatment of epilepsy.[82] Many studies have found that tolerance develops to the anticonvulsant properties of clonazepam with chronic use, which limits its long-term effectiveness as an anticonvulsant.[26]

Abrupt or over-rapid withdrawal from clonazepam may result in the development of the benzodiazepine withdrawal syndrome, causing psychosis characterised by dysphoric manifestations, irritability, aggressiveness, anxiety, and hallucinations.[83] [84] [85] Sudden withdrawal may also induce the potentially life-threatening condition, status epilepticus. Anti-epileptic drugs, benzodiazepines such as clonazepam in particular, should be reduced in dose slowly and gradually when discontinuing the drug to mitigate withdrawal effects.[64] Carbamazepine has been tested in the treatment of clonazepam withdrawal but was found to be ineffective in preventing clonazepam withdrawal-induced status epilepticus from occurring.[86]

Overdose

See main article: Benzodiazepine overdose. Excess doses may result in:

Coma can be cyclic, with the individual alternating from a comatose state to a hyper-alert state of consciousness, which occurred in a four-year-old boy who overdosed on clonazepam.[87] The combination of clonazepam and certain barbiturates (for example, amobarbital), at prescribed doses has resulted in a synergistic potentiation of the effects of each drug, leading to serious respiratory depression.[88]

Overdose symptoms may include extreme drowsiness, confusion, muscle weakness, and fainting.[89]

Detection in biological fluids

Clonazepam and 7-aminoclonazepam may be quantified in plasma, serum, or whole blood in order to monitor compliance in those receiving the drug therapeutically. Results from such tests can be used to confirm the diagnosis in potential poisoning victims or to assist in the forensic investigation in a case of fatal overdosage. Both the parent drug and 7-aminoclonazepam are unstable in biofluids, and therefore specimens should be preserved with sodium fluoride, stored at the lowest possible temperature and analyzed quickly to minimize losses.[90]

Special precautions

The elderly metabolize benzodiazepines more slowly than younger people and are also more sensitive to the effects of benzodiazepines, even at similar blood plasma levels. Doses for the elderly are recommended to be about half of that given to younger adults and are to be administered for no longer than two weeks. Long-acting benzodiazepines such as clonazepam are not generally recommended for the elderly due to the risk of drug accumulation.[13]

The elderly are especially susceptible to increased risk of harm from motor impairments and drug accumulation side effects. Benzodiazepines also require special precaution if used by individuals that may be pregnant, alcohol- or drug-dependent, or may have comorbid psychiatric disorders.[91] Clonazepam is generally not recommended for use in elderly people for insomnia due to its high potency relative to other benzodiazepines.[92]

Clonazepam is not recommended for use in those under 18. Use in very young children may be especially hazardous. Of anticonvulsant drugs, behavioural disturbances occur most frequently with clonazepam and phenobarbital.[91] [93]

Doses higher than 0.5–1 mg per day are associated with significant sedation.[94]

Clonazepam may aggravate hepatic porphyria.[95] [96]

Clonazepam is not recommended for patients with chronic schizophrenia. A 1982 double-blinded, placebo-controlled study found clonazepam increases violent behavior in individuals with chronic schizophrenia.[97]

Clonazepam has similar effectiveness to other benzodiazepines at often a lower dose.[98]

Interactions

Clonazepam decreases the levels of carbamazepine,[99] [100] and, likewise, clonazepam's level is reduced by carbamazepine. Azole antifungals, such as ketoconazole, may inhibit the metabolism of clonazepam.[13] Clonazepam may affect levels of phenytoin (diphenylhydantoin).[99] [101] [102] [103] In turn, Phenytoin may lower clonazepam plasma levels by increasing the speed of clonazepam clearance by approximately 50% and decreasing its half-life by 31%.[104] Clonazepam increases the levels of primidone[102] and phenobarbital.[105]

Combined use of clonazepam with certain antidepressants, anticonvulsants (such as phenobarbital, phenytoin, and carbamazepine), sedative antihistamines, opiates, and antipsychotics, nonbenzodiazepines (such as zolpidem), and alcohol may result in enhanced sedative effects.[13]

Pregnancy

There is some medical evidence of various malformations (for example, cardiac or facial deformations when used in early pregnancy); however, the data is not conclusive. The data are also inconclusive on whether benzodiazepines such as clonazepam cause developmental deficits or decreases in IQ in the developing fetus when taken by the mother during pregnancy. Clonazepam, when used late in pregnancy, may result in the development of a severe benzodiazepine withdrawal syndrome in the neonate. Withdrawal symptoms from benzodiazepines in the neonate may include hypotonia, apnoeic spells, cyanosis, and impaired metabolic responses to cold stress.[106]

The safety profile of clonazepam during pregnancy is less clear than that of other benzodiazepines, and if benzodiazepines are indicated during pregnancy, chlordiazepoxide and diazepam may be a safer choice. The use of clonazepam during pregnancy should only occur if the clinical benefits are believed to outweigh the clinical risks to the fetus. Caution is also required if clonazepam is used during breastfeeding. Possible adverse effects of use of benzodiazepines such as clonazepam during pregnancy include: miscarriage, malformation, intrauterine growth retardation, functional deficits, carcinogenesis, and mutagenesis. Neonatal withdrawal syndrome associated with benzodiazepines include hypertonia, hyperreflexia, restlessness, irritability, abnormal sleep patterns, inconsolable crying, tremors, or jerking of the extremities, bradycardia, cyanosis, suckling difficulties, apnea, risk of aspiration of feeds, diarrhea and vomiting, and growth retardation. This syndrome can develop between three days to three weeks after birth and can have a duration of up to several months. The pathway by which clonazepam is metabolized is usually impaired in newborns. If clonazepam is used during pregnancy or breastfeeding, it is recommended that serum levels of clonazepam are monitored and that signs of central nervous system depression and apnea are also checked for. In many cases, non-pharmacological treatments, such as relaxation therapy, psychotherapy, and avoidance of caffeine, can be an effective and safer alternative to the use of benzodiazepines for anxiety in pregnant women.[107]

Pharmacology

Mechanism of action

Clonazepam enhances the activity of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the central nervous system to give its anticonvulsant, skeletal muscle relaxant, and anxiolytic effects.[108] It acts by binding to the benzodiazepine site of the GABA receptors, which enhances the electric effect of GABA binding on neurons, resulting in an increased influx of chloride ions into the neurons. This further results in an inhibition of synaptic transmission across the central nervous system.[109] [110]

Benzodiazepines do not have any effect on the levels of GABA in the brain.[111] Clonazepam has no effect on GABA levels and has no effect on gamma-aminobutyric acid transaminase. Clonazepam does, however, affect glutamate decarboxylase activity. It differs from other anticonvulsant drugs it was compared to in a study.[112]

Clonazepam's primary mechanism of action is the modulation of GABA function in the brain, by the benzodiazepine receptor, located on GABAA receptors, which, in turn, leads to enhanced GABAergic inhibition of neuronal firing. Benzodiazepines do not replace GABA, but instead enhance the effect of GABA at the GABAA receptor by increasing the opening frequency of chloride ion channels, which leads to an increase in GABA's inhibitory effects and resultant central nervous system depression.[13] In addition, clonazepam decreases the utilization of 5-HT (serotonin) by neurons[113] [114] and has been shown to bind tightly to central-type benzodiazepine receptors.[115] Because clonazepam is effective in low milligram doses (0.5 mg clonazepam = 10 mg diazepam),[116] [117] it is said to be among the class of "highly potent" benzodiazepines.[118] The anticonvulsant properties of benzodiazepines are due to the enhancement of synaptic GABA responses, and the inhibition of sustained, high-frequency repetitive firing.[119]

Benzodiazepines, including clonazepam, bind to mouse glial cell membranes with high affinity.[120] [121] Clonazepam decreases release of acetylcholine in the feline brain[122] and decreases prolactin release in rats.[123] Benzodiazepines inhibit cold-induced thyroid-stimulating hormone (also known as TSH or thyrotropin) release.[124] Benzodiazepines act via micromolar benzodiazepine binding sites as Ca2+ channel blockers and significantly inhibit depolarization-sensitive calcium uptake in experimentation on rat brain cell components. This has been conjectured as a mechanism for high-dose effects on seizures in the study.[125]

Clonazepam is a 2'-chlorinated derivative of nitrazepam, which increases its potency due to electron-attracting effect of the halogen in the ortho-position.[126] [10]

Pharmacokinetics

Clonazepam is lipid-soluble, rapidly crosses the blood–brain barrier, and penetrates the placenta. It is extensively metabolised into pharmacologically inactive metabolites, with only 2% of the unchanged drug excreted in the urine.[127] Clonazepam is metabolized extensively via nitroreduction by cytochrome P450 enzymes, including CYP3A4. Erythromycin, clarithromycin, ritonavir, itraconazole, ketoconazole, nefazodone, cimetidine, and grapefruit juice are inhibitors of CYP3A4 and can affect the metabolism of benzodiazepines.[128] It has an elimination half-life of 19–60 hours.[13] Peak blood concentrations of 6.5–13.5 ng/mL were usually reached within 1–2 hours following a single 2 mg oral dose of micronized clonazepam in healthy adults. In some individuals, however, peak blood concentrations were reached at 4–8 hours.[129]

Clonazepam passes rapidly into the central nervous system, with levels in the brain corresponding with levels of unbound clonazepam in the blood serum.[130] Clonazepam plasma levels are very unreliable amongst patients. Plasma levels of clonazepam can vary as much as tenfold between different patients.[131]

Clonazepam has plasma protein binding of 85%.[132] [127] Clonazepam passes through the blood–brain barrier easily, with blood and brain levels corresponding equally with each other.[133] The metabolites of clonazepam include 7-aminoclonazepam, 7-acetaminoclonazepam and 3-hydroxy clonazepam.[5] [134] These metabolites are excreted by the kidney.[127]

It is effective for 6–8 hours in children, and 8–12 in adults.[135]

Society and culture

Recreational use

See also: Benzodiazepine misuse. A 2006 US government study of hospital emergency department (ED) visits found that sedative-hypnotics were the most frequently implicated pharmaceutical drug in visits, with benzodiazepines accounting for the majority of these. Clonazepam was the second most frequently implicated benzodiazepine in ED visits. Alcohol alone was responsible for over twice as many ED visits as clonazepam in the same study. The study examined the number of times the non-medical use of certain drugs was implicated in an ED visit. The criteria for non-medical use in this study were purposefully broad, and include, for example, drug abuse, accidental or intentional overdose, or adverse reactions resulting from legitimate use of the medication.[136]

Formulations

Clonazepam was approved in the United States as a generic drug in 1997 and is now manufactured and marketed by several companies.

Clonazepam is available as tablets and orally disintegrating tablets (wafers) an oral solution (drops), and as a solution for injection or intravenous infusion.[137]

Crime

In some countries, clonazepam is used by criminals to subdue their victims.[138]

Brand names

It is marketed under the trade name Rivotril by Roche in Argentina, Australia, Austria, Bangladesh, Belgium, Brazil, Canada, Colombia, Costa Rica, Croatia, the Czech Republic, Denmark, Estonia,[139] Germany, Hungary, Iceland, Ireland, Italy, China, Mexico, the Netherlands, Norway, Portugal, Peru, Pakistan, Romania, Serbia, South Africa, South Korea, Spain, Turkey, and the United States; Emcloz, Linotril, Lonazep, Clotrin and Clonotril in India and other parts of Europe; under the name Riklona in Indonesia and Malaysia; and under the trade name Klonopin by Roche in the United States. Other names, such as Antelepsin, Clonoten, Ravotril, Rivotril, Iktorivil, Clonex (Israel), Paxam, Petril, Naze, Zilepam and Kriadex, are used throughout the world. In August 2021, Roche Australia transferred Rivotril to Pharmaco Australia Ltd.[140]

Further reading

Notes and References

  1. News: Clonazepam International. Drugs.com. live. https://web.archive.org/web/20170825060941/https://www.drugs.com/international/clonazepam.html. 25 August 2017.
  2. Web site: Clonazepam Use During Pregnancy . Drugs.com . 4 May 2020 . 17 May 2020 . 28 July 2020 . https://web.archive.org/web/20200728161048/https://www.drugs.com/pregnancy/clonazepam.html . live .
  3. Longo LP, Johnson B . Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives . American Family Physician . 61 . 7 . 2121–2128 . April 2000 . 10779253 . 11 December 2022 . 12 May 2008 . https://web.archive.org/web/20080512180747/http://www.aafp.org/afp/20000401/2121.html . live .
  4. Book: Hupp JR, Tucker MR, Ellis E . Contemporary Oral and Maxillofacial Surgery - E-Book . 2013 . Elsevier Health Sciences . 9780323226875 . 679 .
  5. Ebel S, Schütz H . [Studies on the detection of clonazepam and its main metabolites considering in particular thin-layer chromatography discrimination of nitrazepam and its major metabolic products (author's transl)] . Arzneimittel-Forschung . 27 . 2 . 325–337 . February 1977 . 577149 .
  6. Steentoft A, Linnet K . Blood concentrations of clonazepam and 7-aminoclonazepam in forensic cases in Denmark for the period 2002-2007 . Forensic Science International . 184 . 1–3 . 74–79 . January 2009 . 19150586 . 10.1016/j.forsciint.2008.12.004 .
  7. Web site: Clonazepam . The American Society of Health-System Pharmacists . 15 August 2015 . live . https://web.archive.org/web/20150905085907/http://www.drugs.com/monograph/clonazepam.html . 5 September 2015 .
  8. Book: Basit H, Kahwaji CI . Clonazepam . 2024 . StatPearls . http://www.ncbi.nlm.nih.gov/books/NBK556010/ . 2024-03-15 . Treasure Island (FL) . StatPearls Publishing . 32310470 .
  9. Koubeissi M . Intravenous Clonazepam in Status Epilepticus . Epilepsy Currents . 16 . 2 . 89–90 . 2016 . 27073337 . 4822737 . 10.5698/1535-7511-16.2.89 .
  10. Book: Cooper G . Therapeutic uses of botulinum toxin. 2007. Humana Press. Totowa, N.J.. 9781597452472. 214. live. https://web.archive.org/web/20160819100221/https://books.google.ca/books?id=UIUhCmMtqq8C&pg=PA214. 19 August 2016.
  11. Web site: Paxam Data Sheet . October 18, 2023 . March 14, 2024 . medsafe.govt.nz . 9 December 2023 . https://web.archive.org/web/20231209033635/https://www.medsafe.govt.nz/profs/datasheet/p/Paxamtab.pdf . live .
  12. Edinoff AN, Nix CA, Hollier J, Sagrera CE, Delacroix BM, Abubakar T, Cornett EM, Kaye AM, Kaye AD . Benzodiazepines: Uses, Dangers, and Clinical Considerations . Neurology International . 13 . 4 . 594–607 . November 2021 . 34842811 . 8629021 . 10.3390/neurolint13040059 . free .
  13. Riss J, Cloyd J, Gates J, Collins S . Benzodiazepines in epilepsy: pharmacology and pharmacokinetics . Acta Neurologica Scandinavica . 118 . 2 . 69–86 . August 2008 . 18384456 . 10.1111/j.1600-0404.2008.01004.x . 24453988 .
  14. Book: Fischer J, Ganellin CR . Analogue-based Drug Discovery . 2006 . John Wiley & Sons . 9783527607495 . 535 . 28 July 2020 . 14 January 2023 . https://web.archive.org/web/20230114172419/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA535 . live .
  15. Book: Shorter E . A Historical Dictionary of Psychiatry. 2005. Oxford University Press. 9780190292010. https://books.google.com/books?id=juAJCAAAQBAJ&pg=PT66. B. live. https://web.archive.org/web/20151002125926/https://books.google.ca/books?id=juAJCAAAQBAJ&pg=PT66. 2 October 2015.
  16. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  17. Web site: Clonazepam - Drug Usage Statistics . ClinCalc . 14 January 2024 . 29 April 2017 . https://web.archive.org/web/20170429114759/https://clincalc.com/DrugStats/Drugs/Clonazepam . live .
  18. Book: Martino D, Cavanna AE . Advances in the neurochemistry and neuropharmacology of Tourette Syndrome. 2013. Elsevier Science . Burlington . 9780124115613 . 357 . In several countries, prescription and use is now severely limited due to abusive recreational use of clonazepam.. live. https://web.archive.org/web/20151002132021/https://books.google.ca/books?id=RYhqAAAAQBAJ&pg=PA357. 2 October 2015.
  19. Book: Fisher GL . Encyclopedia of substance abuse prevention, treatment, & recovery . 2009 . SAGE . Los Angeles . 9781412950848. 100. frequently abused. live. https://web.archive.org/web/20160812092733/https://books.google.ca/books?id=CGxXIspuXVMC&pg=PT134. 12 August 2016.
  20. Rossetti AO, Reichhart MD, Schaller MD, Despland PA, Bogousslavsky J . Propofol treatment of refractory status epilepticus: a study of 31 episodes . Epilepsia . 45 . 7 . 757–763 . July 2004 . 15230698 . 10.1111/j.0013-9580.2004.01904.x . 350479 . free .
  21. Ståhl Y, Persson A, Petters I, Rane A, Theorell K, Walson P . Kinetics of clonazepam in relation to electroencephalographic and clinical effects . Epilepsia . 24 . 2 . 225–231 . April 1983 . 6403345 . 10.1111/j.1528-1157.1983.tb04883.x . 2017627 .
  22. Web site: Clonazepam: medicine to control seizures or fits, muscle spasms and restless legs syndrome. 6 January 2020. nhs.uk. en. 19 April 2020. 28 July 2020. https://web.archive.org/web/20200728170146/https://www.nhs.uk/medicines/clonazepam/. live.
  23. Dahlin MG, Amark PE, Nergårdh AR . Reduction of seizures with low-dose clonazepam in children with epilepsy . Pediatric Neurology . 28 . 1 . 48–52 . January 2003 . 12657420 . 10.1016/S0887-8994(02)00468-X .
  24. Hrachovy RA, Frost JD, Kellaway P, Zion TE . Double-blind study of ACTH vs prednisone therapy in infantile spasms . The Journal of Pediatrics . 103 . 4 . 641–645 . October 1983 . 6312008 . 10.1016/S0022-3476(83)80606-4 .
  25. Tomson T, Svanborg E, Wedlund JE . Nonconvulsive status epilepticus: high incidence of complex partial status . Epilepsia . 27 . 3 . 276–285 . May–Jun 1986 . 3698940 . 10.1111/j.1528-1157.1986.tb03540.x . 26694857 .
  26. Browne TR . Clonazepam. A review of a new anticonvulsant drug . Archives of Neurology . 33 . 5 . 326–332 . May 1976 . 817697 . 10.1001/archneur.1976.00500050012003 .
  27. Song L, Liu F, Liu Y, Zhang R, Ji H, Jia Y . Clonazepam add-on therapy for drug-resistant epilepsy . The Cochrane Database of Systematic Reviews . 4 . 4 . CD012253 . April 2020 . 32309880 . 7168574 . 10.1002/14651858.CD012253.pub3 .
  28. Cloos JM . The treatment of panic disorder . Current Opinion in Psychiatry . 18 . 1 . 45–50 . January 2005 . 16639183 . 25 September 2007 . live . https://web.archive.org/web/20110404150908/http://www.medscape.com/viewarticle/497207 . 4 April 2011 .
  29. Davidson JR, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH . Treatment of social phobia with clonazepam and placebo . Journal of Clinical Psychopharmacology . 13 . 6 . 423–428 . December 1993 . 8120156 . 10.1097/00004714-199312000-00008 .
  30. Book: de Leon J . A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities. 2 March 2012. Springer Science & Business Media. 978-1-4614-2012-5. en.
  31. Nardi AE, Freire RC, Mochcovitch MD, Amrein R, Levitan MN, King AL, Valença AM, Veras AB, Paes F, Sardinha A, Nascimento I, de-Melo-Neto VL, Dias GP, E Silva AC, Soares-Filho GL, da Costa RT, Mezzasalma MA, de Carvalho MR, de Cerqueira AC, Hallak JE, Crippa JA, Versiani M . A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine . Journal of Clinical Psychopharmacology . 32 . 1 . 120–126 . February 2012 . 22198456 . 10.1097/JCP.0b013e31823fe4bd . 801184 .
  32. Nardi AE, Perna G . Clonazepam in the treatment of psychiatric disorders: an update . International Clinical Psychopharmacology . 21 . 3 . 131–142 . May 2006 . 16528135 . 10.1097/01.yic.0000194379.65460.a6 . 29469943 .
  33. [Restless legs syndrome: diagnosis and treatment. Opinion of Brazilian experts] . Portuguese . Arquivos de Neuro-Psiquiatria . 65 . 3A . 721–727 . September 2007 . 17876423 . 10.1590/S0004-282X2007000400035 . Restless legs syndrome: diagnosis and treatment. Opinion of Brazilian experts . free . 11449/69841 . free .
  34. Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, Costa J, Stiasny-Kolster K, Sampaio C . Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice . Movement Disorders . 23 . 16 . 2267–2302 . December 2008 . 18925578 . 10.1002/mds.22254 . dead . 19 January 2010 . 91440 . https://web.archive.org/web/20091229102940/http://www.movementdisorders.org/publications/ebm_reviews/treatmentofrls.pdf . 29 December 2009 .
  35. Huynh NT, Rompré PH, Montplaisir JY, Manzini C, Okura K, Lavigne GJ . Comparison of various treatments for sleep bruxism using determinants of number needed to treat and effect size . The International Journal of Prosthodontics . 19 . 5 . 435–441 . 2006 . 17323720 .
  36. Ferini-Strambi L, Zucconi M . REM sleep behavior disorder . Clinical Neurophysiology . 111 . Suppl 2 . S136–S140 . September 2000 . 10996567 . 10.1016/S1388-2457(00)00414-4 . 43692512 .
  37. Nelson DE . Akathisia--a brief review . Scottish Medical Journal . 46 . 5 . 133–134 . October 2001 . 11771491 . 10.1177/003693300104600502 . dead . 1 March 2009 . 45721265 . https://web.archive.org/web/20090323083647/http://smj.org.uk/1001/aka1001.htm . 23 March 2009 . subscription .
  38. Horiguchi J, Nishimatsu O, Inami Y . Successful treatment with clonazepam for neuroleptic-induced akathisia . Acta Psychiatrica Scandinavica . 80 . 1 . 106–107 . July 1989 . 2569804 . 10.1111/j.1600-0447.1989.tb01308.x . 27621771 .
  39. Lipton SA, Rosenberg PA . Excitatory amino acids as a final common pathway for neurologic disorders . The New England Journal of Medicine . 330 . 9 . 613–622 . March 1994 . 7905600 . 10.1056/NEJM199403033300907 .
  40. Curtin F, Schulz P . Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis . Journal of Affective Disorders . 78 . 3 . 201–208 . March 2004 . 15013244 . 10.1016/S0165-0327(02)00317-8 .
  41. Gillies D, Sampson S, Beck A, Rathbone J . Benzodiazepines for psychosis-induced aggression or agitation . The Cochrane Database of Systematic Reviews . 4 . 4 . CD003079 . April 2013 . 23633309 . 10.1002/14651858.CD003079.pub3 . free . 10454/16512 .
  42. Zhou L, Chillag KL, Nigro MA . Hyperekplexia: a treatable neurogenetic disease . Brain & Development . 24 . 7 . 669–674 . October 2002 . 12427512 . 10.1016/S0387-7604(02)00095-5 . 40864297 .
  43. Schenck CH, Arnulf I, Mahowald MW . Sleep and sex: what can go wrong? A review of the literature on sleep related disorders and abnormal sexual behaviors and experiences . Sleep . 30 . 6 . 683–702 . June 2007 . 17580590 . 1978350 . 10.1093/sleep/30.6.683 .
  44. Mulleners WM, Chronicle EP . Anticonvulsants in migraine prophylaxis: a Cochrane review . Cephalalgia . 28 . 6 . 585–597 . June 2008 . 18454787 . 10.1111/j.1468-2982.2008.01571.x . 24233098 . free .
  45. Web site: Joint Formulary Committee . British National Formulary (online) . London . BMJ Group and Pharmaceutical Press . 2 February 2020 . 10 June 2021 . https://web.archive.org/web/20210610002537/https://www.medicinescomplete.com/ . live .
  46. Web site: FDA expands Boxed Warning to improve safe use of benzodiazepine drug . U.S. Food and Drug Administration (FDA) . 23 September 2020 . 23 September 2020 . 24 September 2020 . https://web.archive.org/web/20200924002523/https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class . live .
  47. Stacy M . Sleep disorders in Parkinson's disease: epidemiology and management . Drugs & Aging . 19 . 10 . 733–739 . 2002 . 12390050 . 10.2165/00002512-200219100-00002 . 40376995 .
  48. Lander CM, Donnan GA, Bladin PF, Vajda FJ . Some aspects of the clinical use of clonazepam in refractory epilepsy . Clinical and Experimental Neurology . 16 . 325–332 . 1979 . 121707 .
  49. Sorel L, Mechler L, Harmant J . Comparative trial of intravenous lorazepam and clonazepam im status epilepticus . Clinical Therapeutics . 4 . 4 . 326–336 . 1981 . 6120763 .
  50. Wollman M, Lavie P, Peled R . A hypernychthemeral sleep-wake syndrome: a treatment attempt . Chronobiology International . 2 . 4 . 277–280 . 1985 . 3870855 . 10.3109/07420528509055890 .
  51. Book: Aronson JK . Meyler's Side Effects of Psychiatric Drugs (Meylers Side Effects) . 20 November 2008 . Elsevier Science . 978-0-444-53266-4 . 403 .
  52. Web site: Clonazepam Side Effects . 2010 . Drugs.com . live . https://web.archive.org/web/20100428055102/http://www.drugs.com/sfx/clonazepam-side-effects.html . 28 April 2010 .
  53. Book: The interface of neurology internal medicine . 1 September 2007 . Wolters Kluwer Health/Lippincott Williams Wilkins . Philadelphia . 978-0-7817-7906-7 . 963 .
  54. Book: The American Psychiatric Publishing Textbook of Psychopharmacology (Schatzberg, American Psychiatric Publishing Textbook of Psychopharmacology) . 31 July 2009 . American Psychiatric Publishing, Inc. . USA . 978-1-58562-309-9 . 471 .
  55. Web site: Get Some Sleep: Beware the sleeping pill hangover. 21 June 2017. live. https://web.archive.org/web/20170721005429/http://thechart.blogs.cnn.com/2011/06/07/beware-the-sleeping-pill-hangover/. 21 July 2017.
  56. Book: Goswami M, Pandi-Perumal SR, Thorpy MJ . Narcolepsy:: A Clinical Guide . 24 March 2010 . Springer . 978-1-4419-0853-7 . 73 .
  57. Book: Kelsey JE, Newport DJ, Nemeroff CB . Principles of psychopharmacology for mental health professionals . 2006 . Wiley-Liss . Hoboken, N.J. . 978-0-471-25401-0 . 269 .
  58. Book: Lee-chiong T . Sleep Medicine: Essentials and Review . 24 April 2008 . Oxford University Press, USA . 978-0-19-530659-0 . 463–465 .
  59. Book: Trevor AJ, Katzung BG, Masters SB . Katzung Trevor's pharmacology: examination board review . 1 January 2008 . McGraw Hill Medical . New York . 978-0-07-148869-3 . 191 . 28 July 2020 . 14 January 2023 . https://web.archive.org/web/20230114180644/https://books.google.com/books?id=Bvtkl3XUC5AC&pg=PA191 . live .
  60. Sjö O, Hvidberg EF, Naestoft J, Lund M . Pharmacokinetics and side-effects of clonazepam and its 7-amino-metabolite in man . European Journal of Clinical Pharmacology . 8 . 3–4 . 249–254 . April 1975 . 1233220 . 10.1007/BF00567123 . 27095161 .
  61. Alvarez N, Hartford E, Doubt C . Epileptic seizures induced by clonazepam . Clinical EEG . 12 . 2 . 57–65 . April 1981 . 7237847 . 10.1177/155005948101200203 . 39403793 .
  62. Ishizu T, Chikazawa S, Ikeda T, Suenaga E . [Multiple types of seizure induced by clonazepam in an epileptic patient] . ja . No to Hattatsu = Brain and Development . 20 . 4 . 337–339 . July 1988 . 3214607 .
  63. Bang F, Birket-Smith E, Mikkelsen B . Clonazepam in the treatment of epilepsy. A clinical long-term follow-up study . Epilepsia . 17 . 3 . 321–324 . September 1976 . 824124 . 10.1111/j.1528-1157.1976.tb03410.x . 31409580 .
  64. Bruni J . Recent advances in drug therapy for epilepsy . Canadian Medical Association Journal . 120 . 7 . 817–824 . April 1979 . 371777 . 1818965 . PDF .
  65. Rosenfeld WE, Beniak TE, Lippmann SM, Loewenson RB . Adverse behavioral response to clonazepam as a function of Verbal IQ-Performance IQ discrepancy . Epilepsy Research . 1 . 6 . 347–356 . 1987 . 3504409 . 10.1016/0920-1211(87)90059-3 . 40893264 .
  66. Dodds TJ . Prescribed Benzodiazepines and Suicide Risk: A Review of the Literature . The Primary Care Companion for CNS Disorders . 19 . 2 . March 2017 . 28257172 . 10.4088/PCC.16r02037 . free .
  67. White MC, Silverman JJ, Harbison JW . Psychosis associated with clonazepam therapy for blepharospasm . The Journal of Nervous and Mental Disease . 170 . 2 . 117–119 . February 1982 . 7057171 . 10.1097/00005053-198202000-00010 .
  68. Williams A, Gillespie M . Clonazepam-induced incontinence . Annals of Neurology . 6 . 1 . 86 . July 1979 . 507767 . 10.1002/ana.410060127 . 36023934 .
  69. Sandyk R . Urinary incontinence associated with clonazepam therapy . South African Medical Journal = Suid-Afrikaanse Tydskrif vir Geneeskunde . 64 . 7 . 230 . August 1983 . 6879368 .
  70. Anders RJ, Wang E, Radhakrishnan J, Sharifi R, Lee M . Overflow urinary incontinence due to carbamazepine . The Journal of Urology . 134 . 4 . 758–759 . October 1985 . 4032590 . 10.1016/S0022-5347(17)47428-3 .
  71. van der Bijl P, Roelofse JA . Disinhibitory reactions to benzodiazepines: a review . Journal of Oral and Maxillofacial Surgery . 49 . 5 . 519–523 . May 1991 . 2019899 . 10.1016/0278-2391(91)90180-T . free .
  72. Cohen LS, Rosenbaum JF . Clonazepam: new uses and potential problems . The Journal of Clinical Psychiatry . 48 . Suppl . 50–56 . October 1987 . 2889724 .
  73. Lockard JS, Levy RH, Congdon WC, DuCharme LL, Salonen LD . Clonazepam in a focal-motor monkey model: efficacy, tolerance, toxicity, withdrawal, and management . Epilepsia . 20 . 6 . 683–695 . December 1979 . 115680 . 10.1111/j.1528-1157.1979.tb04852.x . 31346286 .
  74. Vining EP . Use of barbiturates and benzodiazepines in treatment of epilepsy . Neurologic Clinics . 4 . 3 . 617–632 . August 1986 . 3528811 . 10.1016/S0733-8619(18)30966-6 .
  75. Bernik MA, Gorenstein C, Vieira Filho AH . Stressful reactions and panic attacks induced by flumazenil in chronic benzodiazepine users . Journal of Psychopharmacology . 12 . 2 . 146–150 . 1998 . 9694026 . 10.1177/026988119801200205 . 24348950 .
  76. Book: Stahl SM . 2014 . Stahl's Essential Psychopharmacology: Prescriber's Guide . 5th . San Diego, CA . Cambridge University Press . 139 . 978-1-107-67502-5 .
  77. Adjeroud S, Tonon MC, Leneveu E, Lamacz M, Danger JM, Gouteux L, Cazin L, Vaudry H . The benzodiazepine agonist clonazepam potentiates the effects of gamma-aminobutyric acid on alpha-MSH release from neurointermediate lobes in vitro . Life Sciences . 40 . 19 . 1881–1887 . May 1987 . 3033417 . 10.1016/0024-3205(87)90046-4 .
  78. Yokota K, Tatebayashi H, Matsuo T, Shoge T, Motomura H, Matsuno T, Fukuda A, Tashiro N . The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics . British Journal of Pharmacology . 135 . 6 . 1547–1555 . March 2002 . 11906969 . 1573270 . 10.1038/sj.bjp.0704608 .
  79. Loiseau P . [Benzodiazepines in the treatment of epilepsy] . L'Encephale . 9 . 4 Suppl 2 . 287B–292B . 1983 . 6373234 .
  80. Scherkl R, Scheuler W, Frey HH . Anticonvulsant effect of clonazepam in the dog: development of tolerance and physical dependence . Archives Internationales de Pharmacodynamie et de Therapie . 278 . 2 . 249–260 . December 1985 . 4096613 .
  81. Crawley JN, Marangos PJ, Stivers J, Goodwin FK . Chronic clonazepam administration induces benzodiazepine receptor subsensitivity . Neuropharmacology . 21 . 1 . 85–89 . January 1982 . 6278355 . 10.1016/0028-3908(82)90216-7 . 24771398 . Jacqueline Crawley .
  82. Bacia T, Purska-Rowińska E, Okuszko S . Clonazepam in the treatment of drug-resistant epilepsy: a clinical short and long term follow-up study . Monographs in Neural Sciences . 5 . 153–159 . 1980 . 7033770 . 10.1159/000387498 . 978-3-8055-0635-9 . Frontiers of Neurology and Neuroscience .
  83. Sironi VA, Miserocchi G, De Riu PL . Clonazepam withdrawal syndrome . Acta Neurologica . 6 . 2 . 134–139 . April 1984 . 6741654 .
  84. Sironi VA, Franzini A, Ravagnati L, Marossero F . Interictal acute psychoses in temporal lobe epilepsy during withdrawal of anticonvulsant therapy . Journal of Neurology, Neurosurgery, and Psychiatry . 42 . 8 . 724–730 . August 1979 . 490178 . 490305 . 10.1136/jnnp.42.8.724 .
  85. Jaffe R, Gibson E . Clonazepam withdrawal psychosis . Journal of Clinical Psychopharmacology . 6 . 3 . 193 . June 1986 . 3711371 . 10.1097/00004714-198606000-00021 .
  86. Sechi GP, Zoroddu G, Rosati G . Failure of carbamazepine to prevent clonazepam withdrawal status epilepticus . Italian Journal of Neurological Sciences . 5 . 3 . 285–287 . September 1984 . 6500901 . 10.1007/BF02043959 . 23094043 .
  87. Welch TR, Rumack BH, Hammond K . Clonazepam overdose resulting in cyclic coma . Clinical Toxicology . 10 . 4 . 433–436 . 1977 . 862377 . 10.3109/15563657709046280 .
  88. Honer WG, Rosenberg RG, Turey M, Fisher WA . Respiratory failure after clonazepam and amobarbital . The American Journal of Psychiatry . 143 . 11 . 1495b–1495 . November 1986 . 3777263 . 10.1176/ajp.143.11.1495b .
  89. Web site: Clonazepam, Prescription Marketed Drugs . live . https://web.archive.org/web/20120425025645/http://drugsdb.eu/drug.php?d=Clonazepam&m=Contract%20Pharmacy%20Services-pa&id=52a03dbc-0510-40ec-8a33-15bf1c404622.xml . 25 April 2012 .
  90. R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 335-337.
  91. Authier N, Balayssac D, Sautereau M, Zangarelli A, Courty P, Somogyi AA, Vennat B, Llorca PM, Eschalier A . Benzodiazepine dependence: focus on withdrawal syndrome . Annales Pharmaceutiques Françaises . 67 . 6 . 408–413 . November 2009 . 19900604 . 10.1016/j.pharma.2009.07.001 .
  92. Wolkove N, Elkholy O, Baltzan M, Palayew M . Sleep and aging: 2. Management of sleep disorders in older people . CMAJ . 176 . 10 . 1449–1454 . May 2007 . 17485699 . 1863539 . 10.1503/cmaj.070335 .
  93. Trimble MR, Cull C . Children of school age: the influence of antiepileptic drugs on behavior and intellect . Epilepsia . 29 . Suppl 3 . S15–S19 . 1988 . 3066616 . 10.1111/j.1528-1157.1988.tb05805.x . 20440040 .
  94. Hollister LE . Dose-ranging studies of clonazepam in man . Psychopharmacology Communications . 1 . 1 . 89–92 . 1975 . 1223993 .
  95. Bonkowsky HL, Sinclair PR, Emery S, Sinclair JF . Seizure management in acute hepatic porphyria: risks of valproate and clonazepam . Neurology . 30 . 6 . 588–592 . June 1980 . 6770287 . 10.1212/WNL.30.6.588 . 21137619 .
  96. Reynolds NC, Miska RM . Safety of anticonvulsants in hepatic porphyrias . Neurology . 31 . 4 . 480–484 . April 1981 . 7194443 . 10.1212/wnl.31.4.480 . 40044726 .
  97. Karson CN, Weinberger DR, Bigelow L, Wyatt RJ . Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial . The American Journal of Psychiatry . 139 . 12 . 1627–1628 . December 1982 . 6756174 . 10.1176/ajp.139.12.1627 .
  98. Web site: Benzodiazepine Equivalency Table: Benzodiazepine Equivalency. 19 February 2018. 28 April 2017. 2 November 2017. https://web.archive.org/web/20171102050448/https://emedicine.medscape.com/article/2172250-overview#a1. live.
  99. Lander CM, Eadie MJ, Tyrer JH . Interactions between anticonvulsants . Proceedings of the Australian Association of Neurologists . 12 . 111–116 . 1975 . 2912 .
  100. Pippenger CE . Clinically significant carbamazepine drug interactions: an overview . Epilepsia . 28 . Suppl 3 . S71–S76 . 1987 . 3319544 . 10.1111/j.1528-1157.1987.tb05781.x . 22680377 .
  101. Saavedra IN, Aguilera LI, Faure E, Galdames DG . Phenytoin/clonazepam interaction . Therapeutic Drug Monitoring . 7 . 4 . 481–484 . August 1985 . 4082246 . 10.1097/00007691-198512000-00022 .
  102. Windorfer A, Sauer W . Drug interactions during anticonvulsant therapy in childhood: diphenylhydantoin, primidone, phenobarbitone, clonazepam, nitrazepam, carbamazepin and dipropylacetate . Neuropadiatrie . 8 . 1 . 29–41 . February 1977 . 321985 . 10.1055/s-0028-1091502 . 9487285 .
  103. Windorfer A, Weinmann HM, Stünkel S . [Laboratory controls in long-term treatment with anticonvulsive drugs (author's transl)] . Monatsschrift Fur Kinderheilkunde . 125 . 3 . 122–128 . March 1977 . 323695 .
  104. Khoo KC, Mendels J, Rothbart M, Garland WA, Colburn WA, Min BH, Lucek R, Carbone JJ, Boxenbaum HG, Kaplan SA . Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam . Clinical Pharmacology and Therapeutics . 28 . 3 . 368–375 . September 1980 . 7408397 . 10.1038/clpt.1980.175 . 21980890 .
  105. Bendarzewska-Nawrocka B, Pietruszewska E, Stepień L, Bidziński J, Bacia T . [Relationship between blood serum luminal and diphenylhydantoin level and the results of treatment and other clinical data in drug-resistant epilepsy] . Neurologia I Neurochirurgia Polska . 14 . 1 . 39–45 . 1980 . 7374896 .
  106. McElhatton PR . The effects of benzodiazepine use during pregnancy and lactation . Reproductive Toxicology . 8 . 6 . 461–475 . 1994 . 7881198 . 10.1016/0890-6238(94)90029-9 . 1994RepTx...8..461M .
  107. Iqbal MM, Sobhan T, Ryals T . Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant . Psychiatric Services . 53 . 1 . 39–49 . January 2002 . 11773648 . 10.1176/appi.ps.53.1.39 . dead . https://web.archive.org/web/20030711015925/http://ps.psychiatryonline.org/cgi/content/full/53/1/39 . 11 July 2003 . subscription .
  108. Web site: FDA clonazepam . 24 January 2019 . 5 October 2019 . https://web.archive.org/web/20191005192927/https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017533s053,020813s009lbl.pdf . live .
  109. Skerritt JH, Johnston GA . Enhancement of GABA binding by benzodiazepines and related anxiolytics . European Journal of Pharmacology . 89 . 3–4 . 193–198 . May 1983 . 6135616 . 10.1016/0014-2999(83)90494-6 .
  110. Lehoullier PF, Ticku MK . Benzodiazepine and beta-carboline modulation of GABA-stimulated 36Cl-influx in cultured spinal cord neurons . European Journal of Pharmacology . 135 . 2 . 235–238 . March 1987 . 3034628 . 10.1016/0014-2999(87)90617-0 .
  111. Varotto M, Roman G, Battistin L . [Pharmacological influences on the brain level and transport of GABA. I) Effect of various antipileptic drugs on brain levels of GABA] . Bollettino della Societa Italiana di Biologia Sperimentale . 57 . 8 . 904–908 . April 1981 . 7272065 .
  112. Battistin L, Varotto M, Berlese G, Roman G . Effects of some anticonvulsant drugs on brain GABA level and GAD and GABA-T activities . Neurochemical Research . 9 . 2 . 225–231 . February 1984 . 6429560 . 10.1007/BF00964170 . 34328063 .
  113. Meldrum BS . Drugs acting on amino acid neurotransmitters . Advances in Neurology . 43 . 687–706 . 1986 . 2868623 .
  114. Jenner P, Pratt JA, Marsden CD . Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT . Advances in Neurology . 43 . 629–643 . 1986 . 2418652 .
  115. Gavish M, Fares F . Solubilization of peripheral benzodiazepine-binding sites from rat kidney . The Journal of Neuroscience . 5 . 11 . 2889–2893 . November 1985 . 2997409 . 6565154 . 10.1523/JNEUROSCI.05-11-02889.1985 .
  116. "Benzodiazepine Equivalency Table" based on NRHA Drug Newsletter, April 1985 and Benzodiazepines: How they Work & How to Withdraw (The Ashton Manual), 2002.http://www.benzo.org.uk/bzequiv.htm
  117. Web site: What are the equivalent doses of oral benzodiazepines?. 25 July 2020. SPS - Specialist Pharmacy Service. en-GB. 26 July 2020. https://web.archive.org/web/20200726031136/https://www.sps.nhs.uk/articles/what-are-the-equivalent-doses-of-oral-benzodiazepines/. dead.
  118. Chouinard G . Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound . The Journal of Clinical Psychiatry . 65 . Suppl 5 . 7–12 . 2004 . 15078112 .
  119. Macdonald RL, McLean MJ . Anticonvulsant drugs: mechanisms of action . Advances in Neurology . 44 . 713–736 . 1986 . 2871724 .
  120. Tardy M, Costa MF, Rolland B, Fages C, Gonnard P . Benzodiazepine receptors on primary cultures of mouse astrocytes . Journal of Neurochemistry . 36 . 4 . 1587–1589 . April 1981 . 6267195 . 10.1111/j.1471-4159.1981.tb00603.x . 34346051 .
  121. Gallager DW, Mallorga P, Oertel W, Henneberry R, Tallman J . [3H]Diazepam binding in mammalian central nervous system: a pharmacological characterization . The Journal of Neuroscience . 1 . 2 . 218–225 . February 1981 . 6267221 . 6564145 . 10.1523/JNEUROSCI.01-02-00218.1981 . PDF . free .
  122. Petkov V, Georgiev VP, Getova D, Petkov VV . Effects of some benzodiazepines on the acetylcholine release in the anterior horn of the lateral cerebral ventricle of the cat . Acta Physiologica et Pharmacologica Bulgarica . 8 . 3 . 59–66 . 1982 . 6133407 .
  123. Grandison L . Suppression of prolactin secretion by benzodiazepines in vivo . Neuroendocrinology . 34 . 5 . 369–373 . 1982 . 6979001 . 10.1159/000123330 .
  124. Camoratto AM, Grandison L . Inhibition of cold-induced TSH release by benzodiazepines . Brain Research . 265 . 2 . 339–343 . April 1983 . 6405978 . 10.1016/0006-8993(83)90353-0 . 5520697 .
  125. Taft WC, DeLorenzo RJ . Micromolar-affinity benzodiazepine receptors regulate voltage-sensitive calcium channels in nerve terminal preparations . Proceedings of the National Academy of Sciences of the United States of America . 81 . 10 . 3118–3122 . May 1984 . 6328498 . 345232 . 10.1073/pnas.81.10.3118 . free . 1984PNAS...81.3118T .
  126. Book: Shorvon S, Perucca E, Fish D, Dodson WE . The Treatment of Epilepsy . 2008 . John Wiley & Sons . 9780470752456 . 366 . en.
  127. Web site: Clonazepam . www.drugbank.ca . 24 January 2019 . 25 January 2019 . https://web.archive.org/web/20190125020432/https://www.drugbank.ca/drugs/DB01068 . live .
  128. Dresser GK, Spence JD, Bailey DG . Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition . Clinical Pharmacokinetics . 38 . 1 . 41–57 . January 2000 . 10668858 . 10.2165/00003088-200038010-00003 . 37743328 .
  129. Web site: Monograph - Clonazepam -- Pharmacokinetics . January 2006 . . 30 December 2007 . 28 August 2021 . https://web.archive.org/web/20210828041043/https://reference.medscape.com/ . live .
  130. Parry GJ . An animal model for the study of drugs in the central nervous system . Proceedings of the Australian Association of Neurologists . 13 . 83–88 . 1976 . 1029011 .
  131. Gerna M, Morselli PL . A simple and sensitive gas chromatographic method for the determination of clonazepam in human plasma . Journal of Chromatography . 116 . 2 . 445–450 . January 1976 . 1245581 . 10.1016/S0021-9673(00)89915-X .
  132. Tokola RA, Neuvonen PJ . Pharmacokinetics of antiepileptic drugs . Acta Neurologica Scandinavica. Supplementum . 97 . 17–27 . 1983 . 6143468 . 10.1111/j.1600-0404.1983.tb01532.x . 25137468 .
  133. Greenblatt DJ, Miller LG, Shader RI . Clonazepam pharmacokinetics, brain uptake, and receptor interactions . The Journal of Clinical Psychiatry . 48 . Suppl . 4–11 . October 1987 . 2822672 .
  134. Edelbroek PM, De Wolff FA . Improved micromethod for determination of underivatized clonazepam in serum by gas chromatography . Clinical Chemistry . 24 . 10 . 1774–1777 . October 1978 . 699288 . 10.1093/clinchem/24.10.1774 . live . PDF . https://web.archive.org/web/20110607123528/http://www.clinchem.org/cgi/reprint/24/10/1774.pdf . 7 June 2011 .
  135. Book: Therapeutic Uses of Botulinum Toxin. 9781597452472. Cooper G . 5 October 2007. Springer.
  136. Web site: Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits . 9 February 2009 . 2006 . . live . https://web.archive.org/web/20140316023656/http://www.samhsa.gov/data/DAWN/files/ED2006/DAWN2k6ED.htm . 16 March 2014 .
  137. Book: Clonazepam . Buckingham R . Martindale: The Complete Drug Reference . London . Pharmaceutical Press . 18 January 2019 . 10 June 2021 . https://web.archive.org/web/20210610002537/https://www.medicinescomplete.com/ . live .
  138. Web site: Carabajal G . 8 December 2022 . Burundanga y Clonazepan. El cóctel de pastillas que usaba una "viuda negra" para doblegar a sus incautos pretendientes . Burundanga and Clonazepan. The cocktail of pills that a "black widow" used to subdue her unwary suitors . Spanish . La Nacion . The Nation . 9 December 2022 . 9 December 2022 . https://web.archive.org/web/20221209215126/https://www.lanacion.com.ar/seguridad/burundanga-y-clonazepan-el-arsenal-de-pastillas-que-usaba-la-viuda-negra-de-los-polvorines-para-nid07122022/ . live .
  139. Web site: Register of Medicinal Products. ravimiregister.ravimiamet.ee. 18 January 2019. 28 August 2021. https://web.archive.org/web/20210828041047/https://ravimiregister.ee/en/default.aspx?pv=HumRavimid.Ravim&vid=55b06c4a-7c15-4164-8f23-74317a1c28ee. live.
  140. Web site: Rivotril . NPS MedicineWise . 13 November 2020 . 9 January 2023 . 7 March 2023 . https://web.archive.org/web/20230307144211/https://www.nps.org.au/medicine-finder/rivotril-tablets . live .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Clonazepam".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.